Advances in Treatment of Stage IV Metastatic Non-Small Cell Lung Cancer: The Role of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and Tyrosine Kinase Inhibitors

See on Scoop.it - iMaritha

We summarize the landmark studies over the past two decades that established the roles of anti-EGFR antibodies and TK inhibitors in Stage IV metastatic NSCLC.

from Tumblr http://ift.tt/2GhtDtM
via IFTTT